These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 23688018)

  • 1. Leptin and the cardiovascular system - a target for therapeutic interventions.
    Beltowski J
    Curr Pharm Des; 2014; 20(4):601-2. PubMed ID: 23688018
    [No Abstract]   [Full Text] [Related]  

  • 2. Transactivation of ErbB receptors by leptin in the cardiovascular system: mechanisms, consequences and target for therapy.
    Bełtowski J; Jazmroz-Wiśniewska A
    Curr Pharm Des; 2014; 20(4):616-24. PubMed ID: 23688012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Future of Cardiovascular Therapeutics.
    MacRae CA; Roden DM; Loscalzo J
    Circulation; 2016 Jun; 133(25):2610-7. PubMed ID: 27324356
    [No Abstract]   [Full Text] [Related]  

  • 4. Adiponectin, Leptin and Cardiovascular Disorders.
    Zhao S; Kusminski CM; Scherer PE
    Circ Res; 2021 Jan; 128(1):136-149. PubMed ID: 33411633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Curcumin and cardiovascular diseases: Focus on cellular targets and cascades.
    Pourbagher-Shahri AM; Farkhondeh T; Ashrafizadeh M; Talebi M; Samargahndian S
    Biomed Pharmacother; 2021 Apr; 136():111214. PubMed ID: 33450488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic potential of neuregulin-1 in cardiovascular disease.
    Mendes-Ferreira P; De Keulenaer GW; Leite-Moreira AF; Brás-Silva C
    Drug Discov Today; 2013 Sep; 18(17-18):836-42. PubMed ID: 23384772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Counter-regulatory renin-angiotensin system in cardiovascular disease.
    Paz Ocaranza M; Riquelme JA; García L; Jalil JE; Chiong M; Santos RAS; Lavandero S
    Nat Rev Cardiol; 2020 Feb; 17(2):116-129. PubMed ID: 31427727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leptin-induced endothelial dysfunction: a target for therapeutic interventions.
    Payne GA; Tune JD; Knudson JD
    Curr Pharm Des; 2014; 20(4):603-8. PubMed ID: 23688011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activating transcription factor 3 in cardiovascular diseases: a potential therapeutic target.
    Zhou H; Li N; Yuan Y; Jin YG; Guo H; Deng W; Tang QZ
    Basic Res Cardiol; 2018 Aug; 113(5):37. PubMed ID: 30094473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Organs-on-chip models for cardiovascular drug development.
    Zimmermann WH
    Cardiovasc Res; 2021 Nov; 117(12):e164-e165. PubMed ID: 34347045
    [No Abstract]   [Full Text] [Related]  

  • 11. Leptin signaling and obesity: cardiovascular consequences.
    Yang R; Barouch LA
    Circ Res; 2007 Sep; 101(6):545-59. PubMed ID: 17872473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of nitroxyl (HNO) in cardiovascular system: From biochemistry to pharmacology.
    Sun HJ; Wu ZY; Cao L; Zhu MY; Nie XW; Huang DJ; Sun MT; Bian JS
    Pharmacol Res; 2020 Sep; 159():104961. PubMed ID: 32474086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. cGMP Signaling in Cardiovascular Diseases: Linking Genotype and Phenotype.
    Dang TA; Schunkert H; Kessler T
    J Cardiovasc Pharmacol; 2020 Jun; 75(6):516-525. PubMed ID: 32487847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular effects of sphingosine-1-phosphate (S1P).
    Levkau B
    Handb Exp Pharmacol; 2013; (216):147-70. PubMed ID: 23563656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relaxin' the Heart: A Novel Therapeutic Modality.
    Raleigh JM; Toldo S; Das A; Abbate A; Salloum FN
    J Cardiovasc Pharmacol Ther; 2016 Jul; 21(4):353-62. PubMed ID: 26589290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular Effects of Urocortin-2: Pathophysiological Mechanisms and Therapeutic Potential.
    Monteiro-Pinto C; Adão R; Leite-Moreira AF; Brás-Silva C
    Cardiovasc Drugs Ther; 2019 Oct; 33(5):599-613. PubMed ID: 31512017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of imperatorin in the cardiovascular system and cancer.
    Nasser MI; Zhu S; Hu H; Huang H; Guo M; Zhu P
    Biomed Pharmacother; 2019 Dec; 120():109401. PubMed ID: 31622950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic potential of A2 adenosine receptor pharmacological regulators in the treatment of cardiovascular diseases, recent progress, and prospective.
    Bahreyni A; Avan A; Shabani M; Ryzhikov M; Fiuji H; Soleimanpour S; Khazaei M; Hassanian SM
    J Cell Physiol; 2019 Feb; 234(2):1295-1299. PubMed ID: 30146778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Testosterone and the cardiovascular system: a comprehensive review of the basic science literature.
    Herring MJ; Oskui PM; Hale SL; Kloner RA
    J Am Heart Assoc; 2013 Jul; 2(4):e000271. PubMed ID: 23842280
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacological approaches to the treatment of oxidative stress-induced cardiovascular dysfunctions.
    Zamora PL; Villamena FA
    Future Med Chem; 2013 Mar; 5(4):465-78. PubMed ID: 23495692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.